Tempus

Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics, recently joined Tempus leaders to discuss how biotechs can leverage multimodal data to accelerate R&D and de-risk programs. A new article recaps their conversation, including the practical hurdles in bridging scientific ideas with actionable development plans. Read now: tempus.co/3QGo4ej

We are honored to be named one of @TIME “10 Most Influential Health and Life Science Companies of 2026.” Inclusion in this list is a testament to the rigorous work of our team and our clinical, research, and technology partners to bridge the gap between data and action at scale. Learn more: tempus.co/4vXX36m

Recently, @bmsnews utilized the Tempus Next Pathways program to address care gaps patients with advanced non-small cell lung cancer (aNSCLC). Deployed across 13 community-based health systems, the Tempus Next Pathways program provided a unified, longitudinal view of the patient journey, delivering actionable insights that helped close 41% of the biomarker testing care gap. Learn more about this work and how Tempus can help unlock insights and accelerate your programs here: tempus.co/3P7KDIn

Our latest article explores the path of Paige Prostate, the first-ever FDA marketing authorization for a software algorithm device to assist users in digital pathology in 2021, and its recent achievement of EU IVDR certification in 2025. The validation of Paige Prostate exemplifies how powerful AI applications can support the critical expertise of physicians to create a new standard of care. Read on: tempus.co/4cPEHM3

A critical opportunity in clinical research is to bridge the gap between the growing number of available trials and the patients who stand to benefit from them. As trial complexity increases, the traditional, manual approach to patient identification presents significant challenges to meeting this need. By automating patient identification, Tempus’ Next Trials platform can help accelerate accrual for active studies and unlock opportunities to advance research programs. Learn more in a new article here: tempus.co/4vL6aat #ACRP2026

Today we announced a multi-faceted collaboration with @KeckMedicineUSC and @KECKSchool_USC aimed at transforming patient care and accelerating research through the power of data and AI. This collaboration is built to drive clinical impact, research scale, and long-term innovation—transforming care delivery across more than 1.5 million annual patient visits to all USC-affiliated hospitals and clinics across Southern California. Learn more: tempus.co/3Qrk41e

Please join us in celebrating #MedicalLaboratoryProfessionalsWeek! While their work is often done behind the scenes, their impact is at the forefront of everything we do. Thank you to each member of our incredible lab team for their expertise, their tireless work, and for being the essential link in our mission to advance precision medicine.

We're looking forward to attending #ACRP2026 to share how our AI-powered technology supports faster trial activation, accurate patient matching, enhanced resource utilization, and a unified approach to help advance your research goals and accelerate clinical trial enrollment. Stop by Booth #716 to meet with our team and experience live demos of Next Trials. Find more information including live session details here: tempus.co/4t1y0Na @ACRPDC

🧬 New study from #ChaeLab @NorthwesternMed & @TempusAI analyzes RNA-seq data from 2,235 mNSCLC patients on 1st-line anti-PD-(L)1 + chemo 🔬 Using TIGIT, FOXP3, PD-L1 & TAM scores, unsupervised clustering revealed 4 distinct immune subtypes with very different survival outcomes 📊 The 4 clusters: 🏜️ Cluster 1 – Immune desert 🔄 Cluster 2 – TAM-enriched 🔥 Cluster 3 – Immune-hot 🧪 Cluster 4 – Myeloid-inflamed (PD-L1 high) 💡 Key takeaway: Tumor immune heterogeneity matters — one-size-fits-all IO may not be enough. Subtype-specific strategies could improve outcomes in #NSCLC @LurieCancer @NUFeinbergMed @NM_Lung @OncoAlert @IASLC

💡Insights from #AACR26 poster "Lauren subtype classification in gastric cancer using deep learning on real-world H&E images" The research team developed a deep learning classifier to automate Lauren subtype assignment in gastric cancer, addressing the inter-observer variability and scalability challenges of manual pathologist review. By analyzing de-identified H&E-stained images from 637 patient samples in the Tempus real-world database, the model achieved robust performance.

We will report financial results for the first quarter of 2026 on Tuesday, May 5, 2026 at 4:30 p.m. ET. Access the live webcast here: edge.media-server.com/mmc/p/rv7jv7ti/

Attend our upcoming live webinar to discover how #MRD data is shaping the cancer care continuum, with practical insights into its application in neoadjuvant, surgical, and surveillance settings. Our expert panelists: Peter A. Prieto, MD; Alan Tan, MD; and Luis E Raez, MD will share case-based examples and discuss the impact of MRD data on clinical decision-making. Register now: tempus.co/4tihLvU

Reminder to join us today, at 10:00 am – 11:00 am PST, for our #AACR26 Spotlight Theater. Kate Sasser, PhD, and Neil Bence, PhD, of @bmsnews are discussing how tethering deep molecular insights to high-velocity Lab-in-the-Loop screening helps de-risk clinical decisions and accelerate life-saving breakthroughs.

We're looking forward to kicking off @AACR in San Diego. Visit us at Booth #2337 to discover how our AI-enabled technologies and multimodal data are helping to advance precision medicine. Experience a live demonstration of Lens, our analytical tool designed to surface critical insights across multimodal data, and see how it is helping accelerate research and innovation. Learn more about Tempus at #AACR26 here: tempus.co/489i9Ev

In a recent episode of @TheImagingWire, Razik Yousfi and Chiranjiv Singh joined @briancasey3 to discuss the future of AI-driven imaging and how Tempus is enabling the next generation of AI development with foundation models. Listen now: youtu.be/AZqNEtEAjv4?si…

We're excited to announce, alongside Predicta Biosciences, the commercial expansion of a co-branded whole-genome sequencing (WGS) assay, currently known as GenoPredicta™, intended for the comprehensive genomic characterization of hematologic malignancies and measurable residual disease (MRD) monitoring. The assay is currently available to our Life Sciences partners to support exploratory research and clinical development programs. Learn more: tempus.co/3QnC8Ju

We're proud to announce the acceptance of 31 abstracts—including one oral presentation—for the @AACR Annual Meeting taking place next week in San Diego. This research underscores the scale and real-world impact of our multimodal dataset and AI-enabled diagnostic solutions. Find more presentation information here: tempus.co/4tKdwch #AACR26

In the first two months since launching Paige Predict, clinicians are already experiencing the impact of this AI-enabled digital pathology application, which predicts 123 clinically actionable and biologically relevant biomarkers and oncogenic molecular pathways across 16 cancer types. In real patient cases, Paige Predict identified insights from the H&E that were confirmed through a variety of definitive testing options, including Tempus xF, IHC, and hotspot panels. Explore these real patient cases below and learn more about digital pathology offerings here: tempus.co/3Q8BD6c

We're excited to announce the launch of an automated clinical update service designed to support guideline-concordant care by placing patients on an “active follow-up” track. This integrated workflow provides clinicians with ongoing therapy monitoring and context-aware notifications seamlessly delivered through Hub, our secure, AI-enabled physician portal. Learn more: tempus.co/48JB0Gl